Evidence-based treatment of voice and speech disorders in Parkinson disease

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 23, Issue 3, 2015, Pages 209-215

  Mahler, Leslie A ^a   Ramig, Lorraine O ^b,c,d   Fox, Cynthia ^d  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d University of Arizona   (United States)

Author keywords

LSVT LOUD; neuroplasticity; Parkinson disease; treatment

Indexed keywords

CLINICAL PRACTICE; EVIDENCE BASED PRACTICE; FACIAL EXPRESSION; HEALTH CARE DELIVERY; HUMAN; PARKINSON DISEASE; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPEECH INTELLIGIBILITY; SPEECH RATE; SWALLOWING; VOCAL CORD; VOICE; VOICE DISORDER; COMPLICATION; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; QUALITY OF LIFE; SPEECH DISORDERS; VOICE DISORDERS;

EVIDENCE-BASED MEDICINE; HUMANS; PARKINSON DISEASE; QUALITY OF LIFE; SPEECH DISORDERS; VOICE DISORDERS;

EID: 84960087400     PISSN: 10689508     EISSN: 15316998     Source Type: Journal    
DOI: 10.1097/MOO.0000000000000151     Document Type: Review

References (66)

1. Schapira AH. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci 2009; 30:41-47.
2. deLau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5:525-535.
3. Ho A, Iansek R, Marigliani C, et al. Speech impairment in a large sample of people with Parkinson's disease. Behav Neurol 1998; 11:131-137.
4. Miller N, Noble E, Jones D, Burn D. Life with communication changes in Parkinson's disease. Age Ageing 2006; 35:235-239.
5. Ho A, Iansek R, Bradshaw JL. Motor instability in Parkinsonian speech intensity. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14:109-116.
6. Baumgartner C, Sapir S, Ramig LO. Voice quality changes following phonatory-respiratory effort treatment (LSVT1) versus respiratory effort treatment for people with Parkinson disease. J Voice 2001; 14:105-114.
7. Sapir S, Spielman J, Ramig LO, et al. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. J Speech Lang Hear Res 2007; 50:899-912.
8. Forrest K, Weismer G, Turner G. Kinematic, acoustic and perceptual analysis of connected speech produced by Parkinsonian and normal geriatric adults. J Acoust Soc Am 1989; 85:2608-2622.
9. Duffy J. Motor speech disorders; substrates, differential diagnosis and management. (3rd ed. pp. 2013; 165-189.
10. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999; 122:1437-1448.
11. Ahlskog J. Beating a dead horse: dopamine and Parkinson disease. Neurology 2007; 69:1701-1711.
12. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318:121-134.
13. Perez K, Ramig LO, Smith M, Dromey C. The Parkinson larynx: tremor and videostroboscopic findings. J Voice 1996; 10:354-361.
14. Smith M, Ramig LO, Dromey C, et al. Intensive voice treatment in Parkinson's disease: laryngostroboscopic findings. J Voice 1995; 9:453-459.
15. Baker K, Ramig LO, Luschei E, Smith M. Thyroarytenoid muscle activity associated with hypophonia in Parkinson disease and aging. Neurology 1998; 51:1592-1598.
16. Vincken W, Gauthier SG, Dollfuss RE, et al. Involvement of upper-airway muscles in extrapyramidal disorders, a cause of airflow limitation. N Engl J Med 1984; 7:438-442.
17. Solomon N, Hixon TJ. Speech breathing in Parkinson's disease. J Speech Hear Res 1993; 36:294-310.
18. Bartels AL, Leenders KI. Parkinson's disease: the syndrome, the pathogen-esis and pathophysiology. Cortex 2009; 45:915-921.
19. Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 2001; 124:2131-2146.
20. Sapir S, Ramig LO, Fox CM. Intensive voice treatment in Parkinson's disease: Lee Silverman Voice Treatment. Expert Rev 2011; 11:815-830.
21. Desmurget M, Grafton ST, Vindras P, et al. The basal ganglia network mediates the planning of movement amplitude. Exp Brain Res 2003; 150:197-209.
22. Schneider S, Diamond SG, Markham DH. Deficits in orofacial sensorimotor function in Parkinson's disease. Ann Neurol 1986; 19:275-282.
23. Gallena S, Smith PJ, Zeffro T, Ludlow CL. Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease. J Speech Hear Res 2001; 44:1284-1299.
24. Arnold C, Gehrig J, Gispert S, et al. Pathomechanisms and compensatory efforts related to Parkinsonian speech. Neuroimage Clin 2014; 4:82-97.
25. Sapir S. Multiple factors are involved in the dysarthria associated with Parkinson's disease: a review with the implications for clinical practice and research. J Speech Lang Hearing Res 2014; 57:1330-1343.
26. DeLetter M, Santens P, VanBorsel J. The effects of levodopa on word intelligibility in Parkinson's disease. J Commun Disord 2005; 38:187-196.
27. Goberman A, Coelho C, Robb M. Phonatory characteristics of Parkinsonian speech before and after morning medication: the ON and OFF states. J Commun Disord 2002; 35:217-239.
28. Pinto S, Ozsancak C, Tripoliti E, et al. Treatments for dysarthria in Parkinson's disease. Lancet Neurol 2004; 3:547-556.
29. Pinto S, Gentil M, Krack P, et al. Changes induced by levodopa and subthalamic nucleus stimulation on Parkinsonian speech. Mov Disord 2005; 20:1507-1515.
30. Ramig LO, Mead C, Scherer R, et al. Voice therapy and Parkinson's disease: a longitudinal study of efficacy. Presented at: The Clinical Dysarthria Conference. San Diego, CA 1988; 4-7; February.
31. Fox C, Morrison C, Ramig L, Sapir S. Current perspectives on the Lee Silverman Voice Treatment (LSVT). Am J Speech Lang Path 2002; 11:111-123.
32. Maas E, Robin DA, Hula SNA, et al. Principles of motor learning in treatment of motor speech disorders. J Speech-Lang Path 2008; 17:277-298.
33. Ramig LO, Countryman S, Thompson L, Horii Y. A comparisonof two forms of intensive speech treatment for Parkinson disease. J Speech Hear Res 1995; 38:1232-1251.
34. Fox C, Ebersbach G, Ramig L, Sapir S. LSVT LOUD and LSVT BIG: behavioral treatment programs for speech and body movement in Parkinson disease. Parkinson's Dis 2012; 2012:391946.
35. Ramig LO, Countryman S, O'Brien C, et al. Intensive speech treatment for patients with Parkinson disease: short and long-term comparison of two techniques. Neurology 1996; 47:1496-1504.
36. Ramig L, Sapir S, Countryman S, et al. Intensive voice treatment (LSVT1) for individuals with Parkinson disease: a two-year follow-up. J Neurol Neurosurg Psychiatry 2001; 71:493-498.
37. Ramig L, Sapir S, Fox C, Countryman S. Changes in vocal intensity following intensive voice treatment (LSVT1) in individuals with Parkinson disease: a comparison with untreated patients and age-matched controls. Mov Disord 2001; 16:79-83.
38. Countryman S, Hicks J, Ramig LO, Smith M. Supraglottal hyperadduction in an individual with Parkinson disease: a clinical treatment note. Am J Speech Lang Path 1997; 6:74-84.
39. deSwart BJM, Willemse SC, Maassen BAM, Horstink MWIM. Improvement of voicing in patients with Parkinson's disease by speech therapy. Neurology 2003; 60:498-500.
40. Tjaden K, Wilding GE. Rate and loudness manipulations in dysarthria: acoustic and perceptual findings. J Speech Lang Hearing Res 2004; 47:766-783.
41. Huber J, Darling M. Effect of Parkinson's disease on the production of structured and unstructured speaking tasks: respiratory physiologic and linguistic considerations. J Speech Lang Hearing Res 2011; 54:33-46.
42. Whitehill TL, Kwan L, Lee FP, Chow MM. Effect of LSVT on lexical tone in speakers with Parkinson's disease. Parkinson's Dis 2011; 2011:897494.
43. Ramig L, Bonitati CM, Lemke JH, Horii Y. Voice treatment for patients with Parkinson disease: development of an approach and preliminary efficacy data. J Med Speech Lang Path 1994; 2:191-209.
44. Sapir S, Ramig LO, Spielman JL, Fox C. Formant centralization ratio: a proposal for a new acoustic measure of dysarthric speech. J Speech Lang Hear Res 2010; 53:114-125.
45. Dromey C, Ramig LO, Johnson A. Phonatory and articulatory changes associated with increased vocal intensity in Parkinson disease: a case study. J Speech Hear Res 1995; 38:751-764.
46. Sapir S, Ramig L, Hoyt P, et al. Speech vocSPL and quality 12 months after intensive voice treatment (LSVT) for Parkinson's disease: a comparison with an alternative speech treatment. Folia Phoniatrica 2002; 54:296-303.
47. Cannito MP, Suiter DM, Beverly D, et al. Sentence intelligibility before and after voice treatment in speakers with idiopathic Parkinson's disease. J Voice 2012; 26:214-219.
48. Smith M, Ramig LO, Dromey C, et al. Intensive voice treatment in Parkinson disease: laryngostroboscopic findings. J Voice 1995; 9:453-459.
49. Ramig L, Dromey C. Aerodynamic mechanisms underlying treatment-related changes in vocal intensity in patients with Parkinson disease. J Speech Hear Res 1996; 39:798-807.
50. El-Sharkawi A, Ramig LO, Logemann JA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry 2002; 71:31-36.
51. Ward EC, Theodoros DG, Murdoch BE, Silburn P. Changes in maximum capacity tongue function following the Lee Silverman Voice Treatment Program. J Med Speech Lang Path 2000; 8:331-335.
52. Huber JE, Stathopolous ET, Ramig LO, Lancaster SL. Respiratory function and variability in individuals with Parkinson disease: pre and post-Lee Silver-man Voice Treatment. J Med Speech Lang Path 2003; 11:185-201.
53. Spielman J, Borod J, Ramig L. Effects of intensive voice treatment (LSVT) on facial expressiveness in Parkinson's disease: preliminary data. Cog Behav Neuro 2003; 16:177-188.
54. Dumer AL, Oster H, McCabe D, et al. Effects of the Lee Silverman Voice Treatment on facial expressivity in Parkinson's disease. J Int Neuropsych Soc 2014; 20:302-312.
55. Liotti M, Ramig LO, Vogel D, et al. Hypophonia in Parkinson's disease. Neural correlates of voice treatment revealed by PET. Neurology 2003; 60:432-440.
56. Narayana S, Fox PT, Zhang W, et al. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis. Hum Brain Map 2010; 31:222-236.
57. Theodoros D, Constantinescu G, Russell TG, et al. Treating the speech disorder in Parkinson's disease online. J Telemed Telecare 2006; 12 (Suppl 3): 88-91.
58. Constantinescu G, Theodoros D, Russell T, et al. Treating disordered speech and voice in Parkinson's disease online: a randomized controlled noninferiority trial. Intl J Lang Comm Disord 2011; 46:1-16.
59. Howell S, Tripoliti E, Pring T. Delivering the Lee Silverman Voice Treatment (LSVT) by web camera: a feasibility study. Int J Lang Comm Disord 2009; 44:287-300.
60. Theodoros E, Ramig O. Telepractice supported delivery of LSVT LOUD. Sem Speech Lang Path 2011; 21:107-119.
61. Halpern E, Ramig O, Matos E, et al. Innovative technology for the assisted delivery of intensive voice treatment (LSVT LOUD) for Parkinson disease. Am J Sp-Lang Path 2012; 21:354-367.
62. Spielman J, Ramig L, Mahler L, et al. Effects of LSVT extended (LSVT-X) on voice and speech in Parkinson disease. Am J Speech Lang Path 2007; 16:95-107.
63. Countryman S, Ramig LO. Effects of intensive voice therapy on voice deficits associated with bilateral thalamotomy in Parkinson's disease: a case study. J Med Speech Lang Path 1993; 1:233-250.
64. Countryman S, Ramig LO, Pawlas A. Speech and voice deficits in Parkinso-nian plus syndromes: can they be treated? J Med Speech Lang Path 1994; 2:211-225.
65. Spielman J, Mahler L, Halpern A, et al. Intensive voice treatment (LSVT LOUD) for Parkinson's disease following deep brain stimulation of the subthalamic nucleus. J Comm Dis 2011; 44:688-700.
66. Tripoliti E, Zrinzo L, Martinez-Torres I, et al. Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease. Neurology 2011; 76:80-86.